PTO/68/25 (08-03) Approved for use through 07/31/2006, OMB 0851-9031
U.S. Peters and Tradespork Office; U.S. DEPARTMENT OF COMMERCE

Under the Papervork Reduction Act of 1906, no persons are multial to respond to a collection of information unless it displays a valid OMB control number. TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A PENDING SECOND APPLICATION BMS PH-7078 A RCC In re Application of Richard E. Olson Application No.: 09/505,788 Filed: 02/17/2000 FOR: CUCCINOYLAMINO RENZUUIAZEPINES AS INHIBITORS OF AB PROTEIN PRODUCTION The owner, BRUTOL MYERS SQUIES, of 100 percent interest in the Instant application nereby discislins, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 and 173 as shortened by any terminal disulatmen filed prior to the grant of any patent granted on ponding second Application Number 19/265.776 of any patent on the puruling second application. The owner hereby agrees that any patent so granted on the Instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns. In making the above discitatmen, the owner does not discisim the terminal part of sure patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted un the second application, as shortened by any terminal disclaimer tiled prior to the patent grant, in the event that any such uranted patent expires for failure to pay a maintenance foe, is held unenforceable, is found it walki by a court of competent jurisdiction, is statutorily discraimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims conceiled by a remainimation conflicato, to released, or is in any manner terminated prior to the expiration of its full statutory term as shortaned by any terminal disclaimer filed prior to its grant. Check either box 1 or 2 below, if appropriate. Fur submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, 1. etc.), the undersigned is empowered to act on behalf of the organization. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful falce statements and the like so made are punishable by tine or imprisurement, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the velidity of the application or any patent issued thereun. 2. The undersigned is an attorney or agent of record. ALDO A. ALGIERI, PRD Typed or printed nemi-203-677-6809 Terminal disclaimer fee under 37 CFR 1.20(d) is included. WARNING: information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. "Stabsmant under 37 CPR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form P (O/SB/80 may be used for molding this statement. See MPEP § 324.

This adjection of information is equired by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to the (and by the USPTO to prucise) an application. Confidentially is governed by 35 U.S.C. (22 eee 37 CFR 1.14. This enfaction is assumeted to take 12 information governed by 35 U.S.C. (22 eee 37 CFR 1.14. This enfaction is assumeted to take 12 information competes, including governed and submitted the competed deplication from to the ISPTO. Time was very depointing upon the individual case. Any comments on the amount of time your require to complete this form endor suggestions for returning this burden, should be sent to the CNIs information Officer, U.S. Patient and Transmitter Office, U.S. Department of Londmerce, P.O. Bux 1450, Alexandria, VA 22313-1459. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND 10: COmmissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1459.

If you need assistance in completing the form, call 1 800-P10-9199 and select option 2.